Gardasil vaccine

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Inflammatory Bowel Disease

Conditions

Inflammatory Bowel Disease

Trial Timeline

Jul 1, 2008 → Apr 1, 2011

NCT ID

NCT00727636

About Gardasil vaccine

Gardasil vaccine is a pre-clinical stage product being developed by Merck for Inflammatory Bowel Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00727636. Target conditions include Inflammatory Bowel Disease.

What happened to similar drugs?

8 of 20 similar drugs in Inflammatory Bowel Disease were approved

Approved (8) Terminated (2) Active (12)

✅Infliximab + Infliximab + InfliximabCelltrionApproved

🔄CT-P13CelltrionPhase 3

🔄Infliximab subcutaneous + Immunosuppressive AgentsCelltrionPhase 3

✅fidaxomicinAstellas PharmaApproved

✅RisankizumabAbbVieApproved

✅Human Papillomavirus VaccineMerckApproved

✅BezlotoxumabMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01446718	Pre-clinical	Completed	Dec 15, 2014	Jun 30, 2018	Human Papillomavirus
NCT01489527	Pre-clinical	Completed	Sep 1, 2012	Dec 1, 2014	Sexual Transmission of Infection
NCT00727636	Pre-clinical	Completed	Jul 1, 2008	Apr 1, 2011	Inflammatory Bowel Disease

Competing Products

20 competing products in Inflammatory Bowel Disease

See all competitors

Product	Company	Stage	Hype Score
Infliximab + Infliximab + Infliximab	Celltrion	Approved	50
CT-P13	Celltrion	Phase 3	36
Subcutaneous infliximab CT-P13 Remsima®SC	Celltrion	Pre-clinical	22
Infliximab subcutaneous + Immunosuppressive Agents	Celltrion	Phase 3	47
fidaxomicin	Astellas Pharma	Approved	43
Eribulin + Adriamycin + Cyclophosphamide	Eisai	Phase 2	39
E6007 + E6007 + E6007 + E6007 + E6007 + E6007	Eisai	Phase 1	29
Placebo + MORF-057	Eli Lilly	Phase 2	42
Baricitinib + Baricitinib	Eli Lilly	Phase 2	35
LY3114062 SC + Placebo + LY3114062 IV	Eli Lilly	Phase 1	29
MORF-057 + Placebo	Eli Lilly	Phase 2	39
MORF-057	Eli Lilly	Phase 2	35
LY3009104	Eli Lilly	Phase 1	29
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	31
Risankizumab	AbbVie	Approved	43
GC012F Injection infusion	AstraZeneca	Phase 1	36
AZD6793 + Placebo	AstraZeneca	Phase 1	29
Human Papillomavirus Vaccine	Merck	Approved	43
Pembrolizumab	Merck	Phase 2	31
Bezlotoxumab	Merck	Approved	35